MARKET

LYEL

LYEL

Lyell Immunopharma, Inc.
NASDAQ
25.25
-0.21
-0.82%
After Hours: 25.25 0 0.00% 17:02 12/05 EST
OPEN
25.38
PREV CLOSE
25.46
HIGH
25.74
LOW
24.86
VOLUME
33.66K
TURNOVER
--
52 WEEK HIGH
25.74
52 WEEK LOW
7.65
MARKET CAP
535.76M
P/E (TTM)
-1.1343
1D
5D
1M
3M
1Y
5Y
1D
Lyell Immunopharma files to sell 1.9M shares of common stock for holders
TipRanks · 13h ago
Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement
TipRanks · 13h ago
LYELL IMMUNOPHARMA FILES FOR PROPOSED RESALE FROM TIME TO TIME BY INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LIMITED OF UP TO 1.9 MLN SHARES
Reuters · 13h ago
Lyell Immunopharma Updates Bylaws on Stockholder Proposals and Voting Standards
Reuters · 14h ago
Bank of America Securities Keeps Their Sell Rating on Lyell Immunopharma (LYEL)
TipRanks · 4d ago
Weekly Report: what happened at LYEL last week (1124-1128)?
Weekly Report · 5d ago
Lyell Immunopharma Price Target Raised to $20.00/Share From $10.00 by HC Wainwright & Co.
Dow Jones · 11/24 13:02
Lyell Immunopharma Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 11/24 13:02
More
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Webull offers Lyell Immunopharma Inc stock information, including NASDAQ: LYEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYEL stock methods without spending real money on the virtual paper trading platform.